SI1395567T1 - 4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj - Google Patents

4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj

Info

Publication number
SI1395567T1
SI1395567T1 SI200230797T SI200230797T SI1395567T1 SI 1395567 T1 SI1395567 T1 SI 1395567T1 SI 200230797 T SI200230797 T SI 200230797T SI 200230797 T SI200230797 T SI 200230797T SI 1395567 T1 SI1395567 T1 SI 1395567T1
Authority
SI
Slovenia
Prior art keywords
piperazinyl
phenyl
methyl
treatment
gastrointestinal disorders
Prior art date
Application number
SI200230797T
Other languages
English (en)
Inventor
William Brown
Christopher Walpole
Niklas Plobeck
Hudzik Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101772A external-priority patent/SE0101772D0/xx
Priority claimed from SE0103820A external-priority patent/SE0103820D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1395567T1 publication Critical patent/SI1395567T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
SI200230797T 2001-05-18 2002-05-16 4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj SI1395567T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101772A SE0101772D0 (sv) 2001-05-18 2001-05-18 Novel compounds
SE0103820A SE0103820D0 (sv) 2001-11-15 2001-11-15 Novel compounds
EP02733712A EP1395567B1 (en) 2001-05-18 2002-05-16 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
PCT/SE2002/000956 WO2002094794A1 (en) 2001-05-18 2002-05-16 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders

Publications (1)

Publication Number Publication Date
SI1395567T1 true SI1395567T1 (sl) 2009-04-30

Family

ID=26655470

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230797T SI1395567T1 (sl) 2001-05-18 2002-05-16 4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj

Country Status (32)

Country Link
US (3) US7229994B2 (sl)
EP (2) EP1395567B1 (sl)
JP (2) JP4549024B2 (sl)
KR (2) KR100915263B1 (sl)
CN (1) CN1269805C (sl)
AR (1) AR035974A1 (sl)
AT (1) ATE420866T1 (sl)
AU (1) AU2002305994B2 (sl)
BG (1) BG108333A (sl)
BR (1) BR0209678A (sl)
CA (1) CA2446326C (sl)
CO (1) CO5540309A2 (sl)
CY (1) CY1108913T1 (sl)
CZ (1) CZ20033092A3 (sl)
DE (1) DE60230869D1 (sl)
DK (1) DK1395567T3 (sl)
EE (1) EE05243B1 (sl)
ES (1) ES2319876T3 (sl)
HK (1) HK1061237A1 (sl)
HU (1) HUP0401086A3 (sl)
IL (2) IL158631A0 (sl)
IS (1) IS2625B (sl)
MX (1) MXPA03010445A (sl)
MY (1) MY140070A (sl)
NO (1) NO326632B1 (sl)
NZ (2) NZ529401A (sl)
PL (1) PL367142A1 (sl)
PT (1) PT1395567E (sl)
RU (1) RU2297412C2 (sl)
SI (1) SI1395567T1 (sl)
SK (1) SK287555B6 (sl)
WO (1) WO2002094794A1 (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158631A0 (en) 2001-05-18 2004-05-12 Astrazeneca Ab 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
RU2314809C2 (ru) 2001-10-29 2008-01-20 Маунт Кук Байосайенсиз, Инк. Способ лечения депрессии соединениями-агонистами дельта-рецепторов
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
MX2007001240A (es) * 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
CN101128447A (zh) * 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI449692B (zh) 2005-05-13 2014-08-21 Otsuka Pharma Co Ltd 吡咯烷化合物（三）
CN101282953A (zh) * 2005-08-08 2008-10-08 阿斯利康(瑞典)有限公司 治疗剂
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CA2653497A1 (en) * 2006-05-26 2007-12-06 Neuromed Pharmaceuticals Ltd. Heterocyclic compounds as calcium channel blockers
WO2008033299A2 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
MX2010012325A (es) * 2008-05-20 2010-12-02 Astrazeneca Ab Metodo para tratar trastorno ansioso depresivo mayor.
AU2009260905B2 (en) 2008-06-20 2012-08-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN104163788A (zh) * 2014-07-07 2014-11-26 湖南华腾制药有限公司 一种吡啶衍生物的制备方法
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CN113350348B (zh) * 2020-11-05 2022-03-01 东南大学 一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585209A5 (sl) * 1973-06-29 1977-02-28 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
DK0577171T3 (da) 1989-11-22 2002-06-03 Janssen Pharmaceutica Nv Anvendelse af piperazinacetamidderivater mod reperfusionsskader
US5840896A (en) * 1989-11-22 1998-11-24 Janssen Pharmaceutica, N.V. Method of preventing or limiting reperfusion damage
CA2087004C (en) 1990-08-29 1998-04-21 Noriie Itoh Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
CZ280532B6 (cs) 1990-10-10 1996-02-14 Schering Corporation Pyridinové a pyridin-N-oxidové deriváty diaryl-methyl-piperidinů nebo piperazinů, jejich použití a způsob jejich přípravy, farmaceutický prostředek je obsahující
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5681830A (en) * 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
CN1054850C (zh) 1993-07-30 2000-07-26 德尔塔药物公司 用于治疗的哌嗪化合物
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
ZA9811842B (en) 1997-12-24 2000-06-23 Ortho Mcneil Pharm Inc 4-[aryl(piperidin-4-yl)]aminobenzamides.
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904675D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101765D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
IL158631A0 (en) 2001-05-18 2004-05-12 Astrazeneca Ab 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
SE0101766D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0103313D0 (sv) 2001-10-03 2001-10-03 Astrazeneca Ab Novel compounds
RU2314809C2 (ru) * 2001-10-29 2008-01-20 Маунт Кук Байосайенсиз, Инк. Способ лечения депрессии соединениями-агонистами дельта-рецепторов
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0300105D0 (sv) 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0400027D0 (sv) 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
CN101128447A (zh) 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
MX2010012325A (es) 2008-05-20 2010-12-02 Astrazeneca Ab Metodo para tratar trastorno ansioso depresivo mayor.

Also Published As

Publication number Publication date
HUP0401086A2 (hu) 2004-08-30
BG108333A (bg) 2004-12-30
JP2005508293A (ja) 2005-03-31
JP4549024B2 (ja) 2010-09-22
ES2319876T3 (es) 2009-05-14
HUP0401086A3 (en) 2011-07-28
US7229994B2 (en) 2007-06-12
SK13982003A3 (sk) 2004-04-06
US20070270435A1 (en) 2007-11-22
JP5028500B2 (ja) 2012-09-19
KR20080106586A (ko) 2008-12-08
KR100885100B1 (ko) 2009-02-20
WO2002094794A8 (en) 2004-04-22
SK287555B6 (sk) 2011-01-04
AR035974A1 (es) 2004-07-28
RU2297412C2 (ru) 2007-04-20
DE60230869D1 (de) 2009-03-05
CA2446326A1 (en) 2002-11-28
CO5540309A2 (es) 2005-07-29
EP1395567A1 (en) 2004-03-10
EP2042495A1 (en) 2009-04-01
MXPA03010445A (es) 2004-03-09
CN1269805C (zh) 2006-08-16
CZ20033092A3 (cs) 2004-08-18
US7915413B2 (en) 2011-03-29
CN1527820A (zh) 2004-09-08
EP1395567B1 (en) 2009-01-14
IL158631A0 (en) 2004-05-12
IL158631A (en) 2010-12-30
PT1395567E (pt) 2009-03-26
ATE420866T1 (de) 2009-01-15
PL367142A1 (en) 2005-02-21
CY1108913T1 (el) 2014-07-02
US20040147526A1 (en) 2004-07-29
IS7032A (is) 2003-11-13
AU2002305994B2 (en) 2008-06-26
KR20040000471A (ko) 2004-01-03
EE05243B1 (et) 2009-12-15
US8022074B2 (en) 2011-09-20
WO2002094794A1 (en) 2002-11-28
BR0209678A (pt) 2004-09-14
CA2446326C (en) 2010-12-07
JP2010132670A (ja) 2010-06-17
RU2003131964A (ru) 2005-05-10
NO326632B1 (no) 2009-01-26
MY140070A (en) 2009-11-30
NZ529401A (en) 2005-09-30
EE200300545A (et) 2004-02-16
NO20035120D0 (no) 2003-11-17
KR100915263B1 (ko) 2009-09-03
DK1395567T3 (da) 2009-04-06
NZ539828A (en) 2007-01-26
IS2625B (is) 2010-05-15
US20110039858A1 (en) 2011-02-17
HK1061237A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
HK1061237A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
HUP0302719A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
NO20052698D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
PL368804A1 (en) 4(piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2003278664A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL155874A0 (en) Treatment of anxiety disorders
IL158630A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL366387A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158629A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158700A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP1439864A4 (en) METHODS OF TREATING AND DIAGNOSING TUMORIGENOUS AND / OR ANGIOGENIC DISORDERS USING 32616
EP1440163A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF PAIN DISEASES USING 46566
EP1440169A4 (en) METHOD AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF PAIN-SPECIFIC DISORDERS USING 57749
EP1439862A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF PAIN DISORDERS USING 9805
EP1448152A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF PAINFUL DISORDERS USING 2047
HUP0202416A3 (en) Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma
AU2002363126A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 57749